Hypoxia-inducible factor 1α polymorphisms and early-stage cervical cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 1, 2011, Pages 2-7

  Kim, Yun Hwan ^a   Park, In Ae ^a   Park, Woong Yang ^a   Kim, Jae Weon ^a   Kim, Seung Cheol ^b   Park, Noh Hyun ^a   Song, Yong Sang ^a   Kang, Soon Beom ^a  

^a Seoul National University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

Cervical cancer; HIF 1 ; Lymph node metastasis; Polymorphism; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GYNECOLOGIC SURGERY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ALLELES; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 79951472952     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318204f6e6     Document Type: Article

References (25)

1. Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter (Pubitemid 38648189)
2. Tang X, Zhang Q, Nishitani J, et al. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin Cancer Res. 2007;13:2568-2576. (Pubitemid 46795128)
3. Chen W, Li F, Mead L, et al. Human papillomavirus causes an angiogenic switch in keratinocytes which is sufficient to alter endothelial cell behavior. Virology. 2007;367:168-174. (Pubitemid 47418936)
4. Nakamura M, Bodily JM, Beglin M, et al. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology. 2009;387:442-448.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
6. Markowska J, Grabowski JP, Tomaszewska K, et al. Significance of hypoxia in uterine cervical cancer. Multicentre study. Eur J Gynaecol Oncol. 2007;28:386-388. (Pubitemid 47535551)
7. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res. 2003;9:2234-2240. (Pubitemid 36687648)
8. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000;60:4693-4696.
9. Tanaka H, Yasuda Y, Musha T, et al. Hypoxia correlates with angiogenesis in cervical cancers. Int J Clin Oncol. 2005;10:35-39. (Pubitemid 40379493)
10. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13:167-171. (Pubitemid 32209217)
11. Julia I, Bardos MA. Hypoxia-inducible factor-1 and oncogenic signalling. BioEssays. 2004;26:262-269.
12. Clifford SC, Astuti D, Hooper L, et al. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene. 2001;20:5067-5074. (Pubitemid 32769798)
13. Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24:1779-1783. (Pubitemid 37408141)
14. Ling TS, Shi RH, Zhang GX, et al. Common single nucleotide polymorphism of hypoxia-inducible factor-1alpha and its impact on the clinicopathological features of esophageal squamous cell carcinoma. Chin J Dig Dis. 2005;6:155-158.
15. Nadaoka J, Horikawa Y, Saito M, et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer. 2008;122:1297-1302. (Pubitemid 351287229)
16. Fransen K, Fenech M, Fredrikson M, et al. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Molecular Carcinogenesis. 2006;45:833-840. (Pubitemid 44646335)
17. Nasr HB, Chahed K, Bouaouina N, et al. Functional vascular endothelial growth factor -2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression. Clin Chim Acta. 2008;395:124-129.
18. Tzanakis N, Gazouli M, Rallis G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006;94:624-630. (Pubitemid 44851925)
19. Ollerenshaw M, Page T, Hammonds J, et al. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004;153:122-126. (Pubitemid 39592144)
20. Sfar S, Hassen E, Saad H, et al. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35:21-28. (Pubitemid 44485531)
21. Chau CH, Permenter MG, Steinberg SM, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther. 2005;4:1222-1225.
22. Konac E, Onen HI, Metindir J, et al. An investigation of relationships between hypoxia-inducible factor-1[alpha] gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev. 2007;31:102-109. (Pubitemid 46680371)
23. Konac E, Dogan I, Onen HI, et al. Genetic variations in the hypoxia-inducible factor-1alpha gene and lung cancer. Exp Biol Med (Maywood). 2009;234:1109-1116.
24. Munoz-Guerra MF, Fernandez-Contreras ME, Moreno AL, et al. Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol. 2009;16:2351-2358.
25. Hebert C, Norris K, Parashar P, et al. Hypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancers. Mol Cancer. 2006;5:3.